missing translation for 'onlineSavingsMsg'
Learn More
Learn More
Invitrogen™ Human PDXP (aa 156-292) Control Fragment Recombinant Protein
Click to view available options
Quantity:
100 μL
Unit Size:
100µL
Description
Highest antigen sequence indentity to the following orthologs: Mouse (92%), Rat (92%). This recombinant protein control fragment may be used for blocking experiments with the corresponding antibody, PA5-51404 (PA5-51404. In IHC/ICC and WB experiments, we recommend a 100x molar excess of the protein fragment control based on the concentration and the molecular weight. Pre-incubate the antibody-protein control fragment mixture for 30 min at room temperature.
Pyridoxal 5-prime-phosphate (PLP) is the active form of vitamin B6 that acts as a coenzyme in maintaining biochemical homeostasis. The preferred degradation route from PLP to 4-pyridoxic acid involves the dephosphorylation of PLP by PDXP. Pyridoxal 5-prime-phosphate (PLP) is the active form of vitamin B6 that acts as a coenzyme in maintaining biochemical homeostasis. The preferred degradation route from PLP to 4-pyridoxic acid involves the dephosphorylation of PLP by PDXP (Jang et al., 2003 ).
Specifications
Specifications
| Accession Number | Q96GD0 |
| Concentration | ≥5.0 mg/mL |
| For Use With (Application) | Blocking Assay, Control |
| Formulation | 1 M urea, PBS with no preservative; pH 7.4 |
| Gene ID (Entrez) | 57026 |
| Name | Human PDXP (aa 156-292) Control Fragment |
| Quantity | 100 μL |
| Regulatory Status | RUO |
| Gene Alias | 1600027H05Rik; AB041662; chronophilin; chronophin; CIN; dJ37E16.5; FLJ32703; PDXP; Plp; PLP phosphatase; PLPP; PLP-phosophatase; pyridoxal (pyridoxine, vitamin B6) phosphatase; pyridoxal phosphatase; pyridoxal phosphate phosphatase; Rbp1; reg I binding protein I; reg I-binding protein 1; testicular secretory protein Li 36 |
| Common Name | PDXP |
| Show More |
Product Content Correction
Your input is important to us. Please complete this form to provide feedback related to the content on this product.
Product Title
Spot an opportunity for improvement?Share a Content Correction